A clinical approach to the investigation and management of long COVID associated neuropathic pain

COVID-19 has been associated with a wide range of ongoing symptoms following recovery from the acute SARS-CoV-2 infection. Around one in three people with COVID-19 develop neurological symptoms with many reporting neuropathic pain and associated symptoms, including paraesthesia, numbness, and dysesthesia. Whilst the pathophysiology of long COVID-19-associated neuropathic pain remains unclear, it is likely to be multifactorial. Early identification, exclusion of common alternative causes, and a biopsychosocial approach to the management of the symptoms can help in relieving the burden of disease and improving the quality of life for patients.

Automated summary

COVID-19 is associated with a range of long-term neurological symptoms, including neuropathic pain, paraesthesia, numbness, and dysesthesia. The underlying causes of these symptoms are still unclear, but a biopsychosocial approach to management and early identification can help improve patients' quality of life.